New combo drug study aims to extend remission in ovarian cancer patients
NCT ID NCT06121401
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study looks at whether adding olaparib to the standard drug bevacizumab can help keep advanced ovarian cancer from coming back after initial chemotherapy. About 190 women with a specific genetic marker (HRD-positive) will receive this combination as maintenance therapy. The goal is to see how many patients remain cancer-free after two years and to better understand who benefits most in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, OVARIAN EPITHELIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Socio Sanitaria Territoriale (ASST) Lariana
San Fermo della Battaglia, Como, 22042, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, Italy, 35128, Italy
Conditions
Explore the condition pages connected to this study.